UNSPSC 51203802: Belatacept

This classification denotes an immunosuppressant with the molecular formula C3508H5440N922O1096S32, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E3B2GI648A, more generally known as belatacept. European Medicines Agency schedules belatacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20603. The term BELATACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, list 59.

UNSPSC 51203802 Belatacept, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The three opportunities tagged to this code — naloxone and drug deactivation systems, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceuticals — diverge substantially from belatacept, an immunosuppressant used in transplant medicine. State and local governments are not actively soliciting belatacept under this code at present.

The recent activity under the code reflects broader state and local pharmaceutical and medical supply procurement across Florida, Texas, and Minnesota, though none targets belatacept specifically. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted an RFI in April 2026 on direct-to-manufacturer prescription programs. The City of Tampa solicited medical and first aid supplies for its Fire Department Rescue Division through an IFB due March 13, 2026, with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The code assignment appears to be a data-quality mismatch rather than a reflection of actual belatacept procurement demand.